Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

TRIL / Trillium Therapeutics Inc. / Baker Brothers Advisors LP - AMENDMENT NO. 1 (Passive Investment)

2018-02-13 sec.gov
    SCHEDULE 13G   SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   Under the Securities Exchange Act of 1934 (Amendment No. 1)*   Trillium Therapeutics, Inc.   (Name of Issuer)   Common Stock, no par value per share   (Title of Class of Securities)   89620X506   (CUSIP number)   December 31, 2017   (Date of event which requires filing of this statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b)   ¨ Rule 13d-1(c)   ¨ Ru

TRIL / Trillium Therapeutics Inc. / Baker Brothers Advisors LP - AMENDMENT NO. 1 (Passive Investment)

2018-02-13 sec.gov
    SCHEDULE 13G   SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   Under the Securities Exchange Act of 1934 (Amendment No. 1)*   Trillium Therapeutics, Inc.   (Name of Issuer)   Common Stock, no par value per share   (Title of Class of Securities)   89620X506   (CUSIP number)   December 31, 2017   (Date of event which requires filing of this statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b)   ¨ Rule 13d-1(c)   ¨ Ru

TRIL / Trillium Therapeutics Inc. / AWM Investment Company, Inc. - TRILLIUM 13G (Passive Investment)

2018-02-13 sec.gov
THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Trillium Therapeutics, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *

TRIL / Trillium Therapeutics Inc. / AWM Investment Company, Inc. - TRILLIUM 13G (Passive Investment)

2018-02-13 sec.gov
THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Trillium Therapeutics, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *

TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-02-09 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 001-36596 ___________________ TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of p

Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter

2018-02-09 marketwired
TORONTO, ONTARIO--(Marketwired - Feb. 9, 2018) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming conferences. (6-0)

TRIL / Trillium Therapeutics Inc. / JANUS CAPITAL MANAGEMENT LLC - JANUS CAPITAL MANAGEMENT 12/31/17 <5% ANNUAL CLOSEOUT (Passive Investment)

2018-02-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: TRILLIUM THERAPEUTICS INC Title of Class of Securities: Common Stock CUSIP Number: 89620X506 Date of Event Which Requires Filing of this Statement: 12/31/2017 Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

TRIL / Trillium Therapeutics Inc. / JANUS CAPITAL MANAGEMENT LLC - JANUS CAPITAL MANAGEMENT 12/31/17 <5% ANNUAL CLOSEOUT (Passive Investment)

2018-02-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: TRILLIUM THERAPEUTICS INC Title of Class of Securities: Common Stock CUSIP Number: 89620X506 Date of Event Which Requires Filing of this Statement: 12/31/2017 Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-01-17 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-36596 ___________________ TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of pr

Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

2018-01-17 marketwired
TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the following key additions to its leadership team: (9-0)

APAC Resources Inc. and XORTX Pharma Corp. Announce Closing of Reverse Take-over, Financing, Consolidation and Name Change

2018-01-10 marketwired
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW. (6-0)

TRIL / Trillium Therapeutics Inc. FORM F-10/A

2018-01-08 sec.gov
Trillium Therapeutics Inc.: Form F-10 - Filed by newsfilecorp.com As filed with the Securities and Exchange Commission on January 8, 2018. Registration No. 333-222085   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRILLIUM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) Ontario, Canada 2834 Not Applicable (Province or other Jurisdiction of (Primary Standard Ind

TRIL / Trillium Therapeutics Inc. FORM F-10/A

2018-01-08 sec.gov
Trillium Therapeutics Inc.: Form F-10 - Filed by newsfilecorp.com As filed with the Securities and Exchange Commission on January 5, 2018. Registration No. 333-222085   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRILLIUM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) Ontario, Canada 2834 Not Applicable (Province or other Jurisdiction of (Primary Standard Ind

ROTY Edition 1 Volume 64: Several Key Updates And Trades

2017-12-19 seekingalpha
While performance for December continues to disappoint, we continue to position the ROTY model account for a profitable 2018. (471-1)


CUSIP: 89620X506